Introduction
Wegovy (semaglutide) is a highly effective medication for obesity management. Its success depends on correct dose titration. Dose escalation should not rely on time alone. It must be guided by patient tolerance and clinical response. As emphasised in the clinical experience of Dr Ali Raja, an individualised approach leads to better outcomes and fewer side effects.
Standard titration protocol
The usual stepwise schedule is:
0.25 mg once weekly for 4 weeks
0.5 mg once weekly for 4 weeks
1 mg once weekly for 4 weeks
1.7 mg once weekly for 4 weeks
Maintenance dose: 2.4 mg once weekly
This schedule is a guide. In real-world practice, flexibility is often required, and as Dr Ali Raja highlights, strict escalation without considering patient tolerance can lead to unnecessary discontinuation.
Target weight loss
A practical early target is around 0.5–1% of body weight per week.
This is commonly equal to 2–4 kg per month in the early phase.
This benchmark helps guide treatment decisions.
When to increase the dose
Increase the dose if the patient tolerates the current dose well and weight loss is below target.
If side effects are minimal but response is limited, escalation can improve efficacy.
When to maintain the same dose
If the patient is tolerating treatment and achieving appropriate weight loss, there is no need to increase the dose.
Many patients respond well at lower doses such as 0.5 mg or 1 mg.
Maintaining the same dose is often the safest and most effective approach.
When not to increase the dose
Avoid dose escalation if the patient has moderate or severe side effects such as nausea, vomiting, or reduced oral intake.
In these situations, continue the current dose longer or consider stepping back.
Key clinical principle
Wegovy is a dose-to-effect medication, not dose-to-maximum.
The goal is not to reach 2.4 mg in every patient.
The aim is to identify the lowest effective dose with acceptable tolerance.
Conclusion
Effective dose titration requires balancing efficacy and tolerability.
If tolerance is good and response is inadequate, increase the dose.
If response is good, continue the current dose.
If side effects occur, delay escalation or reduce the dose.
An individualised approach is essential for long-term success.
This article has been prepared by Dr Ali Raja, a medical doctor with over 30 years of clinical experience, including 15 years as an orthopaedic surgeon overseas, and currently practicing as a GP in Australia for more than three years.
Dr Ali Raja
Phone: 0452 10 20 89
Email: DrAliVic@gmail.com
Website: www.DrAli.au
No comment